- Exceeded EPS Estimates: LifeVantage reported an EPS of $0.26, surpassing the estimated $0.14.
- Revenue Growth: Despite missing estimates, revenue grew by 21.1% year-over-year to $58.44 million.
- Financial Health Indicators: The company showcased a P/E ratio of approximately 19.91 and an adjusted EBITDA increase to $6.4 million.
LifeVantage Corporation (NASDAQ: LFVN) is a health and wellness company that focuses on nutrigenomics, which explores how nutrition and natural compounds can enhance genetic health. The company offers products like the Protandim® family and TrueScience® Liquid Collagen, designed to promote health by working with individual biology. LifeVantage competes in a dynamic market, striving to maintain its innovative edge.
On May 6, 2025, LifeVantage reported its earnings, revealing an EPS of $0.26, which exceeded the estimated $0.14. This indicates strong profitability, as the net income per diluted share doubled from $0.13 a year ago. The adjusted earnings per diluted share also rose to $0.26, up from $0.21 the previous year, showcasing the company’s improved financial performance.
Despite the positive EPS, LifeVantage’s revenue of $58.44 million fell short of the estimated $60.96 million. However, this revenue still marked a 21.1% increase from the same period last year. Excluding foreign currency fluctuations, the revenue growth was approximately 22.1%. The Americas saw a revenue surge of 29.5%, while Asia/Pacific and Europe experienced a decline of 7.2%, or 4.7% when excluding currency impacts.
LifeVantage’s financial metrics provide further insights into its market position. The company has a P/E ratio of approximately 19.91, indicating how the market values its earnings. Its price-to-sales ratio is about 0.71, and the enterprise value to sales ratio is around 0.67, reflecting the market’s valuation of its sales and overall value. The earnings yield is about 5.02%, showing the earnings generated per dollar invested.
The company’s financial health is supported by a debt-to-equity ratio of approximately 0.43, suggesting a moderate level of debt relative to its equity. The current ratio of about 1.66 indicates LifeVantage’s ability to cover short-term liabilities with short-term assets. Additionally, the adjusted EBITDA increased to $6.4 million from $5.1 million a year earlier, highlighting improved operational efficiency.
